The association of improved clinical benefit and PFS with the antiangiogenic phase I trial therapy in patients with TP53 hotspot mutations provided additional evidence that antiangiogenic agent-based phase I trial therapy is appropriate for consideration as matched therapy in patients with TP53 mutant NSCLC. Here, TP53 is linked to non-small cell lung carcinoma.